Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
122.41 USD   +1.15%
12/02Seagen to Highlight ADCETRIS Clinical Progress at the 2022 American Society of Hematology Annual Meeting
AQ
12/01Seagen to Highlight ADCETRIS« (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
BU
11/25Weekly market update : The calm before the storm
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care Stocks Fall on Monday

09/26/2022 | 04:04pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
APOLLO MEDICAL HOLDINGS, INC. 0.25% 28.4 Delayed Quote.-61.35%
DURECT CORPORATION -2.61% 0.3989 Delayed Quote.-59.54%
LAVA THERAPEUTICS N.V. 8.30% 7.31 Delayed Quote.32.91%
NASDAQ COMPOSITE -0.18% 11461.5 Real-time Quote.-26.74%
SEAGEN INC. 1.15% 122.41 Delayed Quote.-20.82%
SIGA TECHNOLOGIES, INC. -4.52% 8.66 Delayed Quote.15.16%
All news about SEAGEN INC.
12/02Seagen to Highlight ADCETRIS Clinical Progress at the 2022 American Society of Hematolo..
AQ
12/01Seagen to Highlight ADCETRIS« (brentuximab vedotin) Clinical Progress at the 2022 Ameri..
BU
11/25Weekly market update : The calm before the storm
MS
11/22Mirati attracts fresh takeover interest - Bloomberg News
RE
11/21Truist Securities Initiates Coverage on Seagen at Hold With $135 Price Target
MT
11/21Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs
RE
11/21Insider Sell: Seagen
MT
11/18Seagen Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S..
AQ
11/15Insider Sell: Seagen
MT
11/15Immunogen's $6,220 ovarian cancer drug to be shipped within days
RE
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 914 M - -
Net income 2022 -655 M - -
Net cash 2022 1 453 M - -
P/E ratio 2022 -34,6x
Yield 2022 -
Capitalization 22 727 M 22 727 M -
EV / Sales 2022 11,1x
EV / Sales 2023 8,63x
Nbr of Employees 2 675
Free-Float 98,9%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 122,41 $
Average target price 165,86 $
Spread / Average Target 35,5%
EPS Revisions
Managers and Directors
David R. Epstein Chief Executive Officer & Director
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer & President-R&D
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-20.82%22 727
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
CELLTRION, INC.-12.12%18 382